1. Home
  2. DSM vs CYBN Comparison

DSM vs CYBN Comparison

Compare DSM & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BNY Mellon Strategic Municipal Bond Fund Inc.

DSM

BNY Mellon Strategic Municipal Bond Fund Inc.

HOLD

Current Price

$5.98

Market Cap

301.5M

Sector

Finance

ML Signal

HOLD

Logo Cybin Inc.

CYBN

Cybin Inc.

HOLD

Current Price

$7.19

Market Cap

298.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSM
CYBN
Founded
1989
2019
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.5M
298.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DSM
CYBN
Price
$5.98
$7.19
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$74.50
AVG Volume (30 Days)
161.7K
646.7K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
3.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.69
$4.81
52 Week High
$6.05
$10.73

Technical Indicators

Market Signals
Indicator
DSM
CYBN
Relative Strength Index (RSI) 50.29 66.78
Support Level $5.93 $6.53
Resistance Level $6.09 $7.21
Average True Range (ATR) 0.06 0.40
MACD -0.00 0.13
Stochastic Oscillator 54.00 95.08

Price Performance

Historical Comparison
DSM
CYBN

About DSM BNY Mellon Strategic Municipal Bond Fund Inc.

BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Share on Social Networks: